ArticleDigestive diseases and sciences2015
Oncogenic miR-23a in Pancreatic Ductal Adenocarcinogenesis Via Inhibiting APAF1.
Article in Digestive diseases and sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Non-coding RNAs underlying the pathophysiological links between type 2 diabetes and pancreatic cancer: A systematic review.Journal of diabetes investigation · 2022Pooled it
- Review
- Functional and Potential Therapeutic Implication of MicroRNAs in Pancreatic Cancer.International journal of molecular sciences · 2023Review
- Microbiome and MicroRNA or Long Non-Coding RNA-Two Modern Approaches to Understanding Pancreatic Ductal Adenocarcinoma.Journal of clinical medicine · 2023Review
- The Link between Diabetes, Pancreatic Tumors, and miRNAs-New Players for Diagnosis and Therapy?International journal of molecular sciences · 2023Review
- MicroRNA-23a-3p influences the molecular mechanism of gastric cancer cells via CCL22/PI3K/Akt axis.Bioengineered · 2021Article
- Roles and Clinical Significances of ATF6, EMC6, and APAF1 in Prognosis of Pancreatic Cancer.Frontiers in genetics · 2021Article
- EMC6 regulates acinar apoptosis via APAF1 in acute and chronic pancreatitis.Cell death & disease · 2020Article
- MicroRNA-23a acts as an oncogene in pancreatic carcinoma by targeting TFPI-2.Experimental and therapeutic medicine · 2020Article
- Hippo/MST blocks breast cancer by downregulating WBP2 oncogene expression via miRNA processor Dicer.Cell death & disease · 2020Article
- Mass spectrometry-based iTRAQ analysis of serum markers in patients with pancreatic cancer.Oncology letters · 2020Article
- Non-coding RNAs in Pancreatic Ductal Adenocarcinoma.Frontiers in oncology · 2020Review
- LncRNA MEG3 inhibits cell proliferation and induces apoptosis in laryngeal cancer via miR-23a/APAF-1 axis.Journal of cellular and molecular medicine · 2019Article
- Review
- Review
- miR-186 promotes tumor growth in cutaneous squamous cell carcinoma by inhibiting apoptotic protease activating factor-1.Experimental and therapeutic medicine · 2018Article
- miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression.Molecular medicine reports · 2018Article
- Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.International journal of molecular sciences · 2017Review
- MicroRNA in pancreatic cancer.Journal of human genetics · 2017Review
- Down-regulated miR-23a Contributes to the Metastasis of Cutaneous Melanoma by Promoting Autophagy.Theranostics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundmiR-23a, which participates in invasion of pancreatic ductal adenocarcinoma cells into the mesothelial barrier, is a critical regulator in many cancers. It, however, is still unknown whether miR-23a regulates pancreatic cell proliferation and apoptosis or not.
aimsWe sought to investigate the role of miR-23a in regulation of pancreatic cell proliferation and apoptosis.
methodsmiRNA, mRNA, and protein expressions were determined by qRT-PCR and Western blot, respectively. Dual-luciferase reporter assay was used in detection for binding ability of miR-23a to APAF1. Ectopic miR-23a and APAF 1 were introduced to pancreatic cells, and their roles in proliferation and apoptosis were detected by MTT, colony formation, and apoptosis assays, respectively.
resultsUp-regulation of miR-23a and down-regulation of APAF 1 were found in pancreatic ductal cancer, respectively. miR-23a significantly inhibited the luciferase activity by targeting APAF 1 3'UTR. Ectopic miR-23a significantly suppressed the APAF 1 gene expression in pancreatic cancer cells. Similar to siAPAF1, miR-23a significantly promoted pancreatic cancer cell proliferation and repressed apoptosis. Furthermore, miR-23a inhibitor and exogenous APAF 1 could recover the effects.
conclusionsIt is suggested that miR-23a, acting as an oncogenic regulator by directly targeting APAF 1 in pancreatic cancer, is a useful potential biomarker in diagnosis and treatment of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.